Huma
UK health-tech firm with FDA/EU-cleared remote monitoring software used across NHS and global hospitals.
On the record
Checkpoint: Confirmation or denial of a reported new funding round
The call
Huma holds real regulatory ground and deep NHS ties, but unclear revenue and a stalled funding clock leave its next move unproven.
Huma builds artificial intelligence software that helps doctors and hospitals manage patient care and write medical notes. It has earned real government approval from the FDA and European regulators that took years to get, which slows down big competitors like Epic and Oracle Health from copying it quickly. However, nobody knows for sure how much money Huma actually makes, the company has not raised a new funding round in nearly two years, and tools from companies like OpenAI are starting to do similar note-writing work without needing that expensive approval. The biggest question is whether Huma can turn all the hospitals it acquired into real, growing revenue, or if it is just collecting customers without actually making money grow.
Why
01
AI pressure: Epic ambient scribing and generic LLM scribe tools. Hi Scribe automates clinical notes, but Epic and generic AI scribes now offer similar documentation tools inside existing EHR systems. Could AI do the core job? Only partly.
02
Bigger players: Epic, Oracle Health, Medtronic CareLink. EHR giants and device makers run their own monitoring and documentation tools, competing directly with Huma inside hospital systems. Could a giant copy it? No, they are blocked.
03
What protects it. Multi-country SaMD regulatory clearances and deployment across two-thirds of UK primary and secondary care providers.
What would change this call
Huma announces or denies a priced Series E (>=$1B) within 6-12 months. Confirms whether fresh institutional capital still backs Huma or funding has stalled.
Epic or Oracle Health publicly expands ambient scribing into remote patient monitoring/SaMD territory. Would show incumbents encroaching directly on Huma's Hi Scribe and RPM turf.
Huma publishes an audited revenue figure or NHS re-tender outcome. Would resolve whether the $40M-$94.5M gap reflects real growth or NHS dependency risk.
Epic or Oracle Health publicly expands ambient scribing into remote patient monitoring/SaMD territory. Would show incumbents encroaching directly on Huma's Hi Scribe and RPM turf.
Huma publishes an audited revenue figure or NHS re-tender outcome. Would resolve whether the $40M-$94.5M gap reflects real growth or NHS dependency risk.
Key numbers
- Series D: $80M, valuation near $1B
- Hi Scribe live in 870 practices
- Deployed in 2/3 of UK care providers
Named risks
- No new priced funding round in over 24 months despite active M&A spending via Eckuity partnership.
- Revenue figures unconfirmed and conflicting, ranging from $40M to $94.5M with no audited disclosure.
- Hi Scribe AI product faces direct erosion from Epic and Oracle Health's native ambient-scribe features.
- Sector graveyard precedent: Babylon, Sensyne Health, and Pear Therapeutics all collapsed in similar digital health niche.
- Heavy dependency on UK NHS contracts exposes Huma to any national health-budget or digital-policy shift.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Epic Systems | losing to | Epic's native ambient-scribe EHR features directly compete with Huma's Hi Scribe tool as of June 2025 |
| Oracle Health | losing to | Oracle Health ships competing AI documentation features against Huma's Hi Scribe as of 2025 |
| Medtronic | contesting | Medtronic's CareLink offers AI-driven remote cardiac and diabetes monitoring, an adjacent incumbent noted February 2026 |
| Biofourmis | gaining on | Peer in remote patient monitoring reported to have undergone restructuring, per CB Insights competitor listing |
| Babylon Health | gaining on | Babylon collapsed into bankruptcy in August 2023, removing a major digital health competitor from the field |
| Current Health (Best Buy) | gaining on | Best Buy divested Current Health, acquired for $400M, effectively winding it down as of June 2025 |
Questions people ask
- Is Huma profitable in 2026?
- No confirmed profitability data exists. Revenue estimates conflict sharply, ranging from $40M in 2023 per CB Insights to $94.5M per ZoomInfo, with no later confirmed figure. Huma remains privately held and has not disclosed audited financials as of July 2026.
- Could AI replace Huma?
- Not the core platform. Huma holds disease-agnostic FDA 510(k) Class II, EU MDR Class IIb, and Health Canada Class II SaMD certifications built over years of regulatory work, a moat generic AI models cannot instantly replicate. Its Hi Scribe AI documentation tool, however, faces direct competition from Epic and Oracle Health's native ambient-scribe features.
- Who owns Huma?
- Huma Therapeutics Limited is privately held, backed by investors including AstraZeneca, Bayer via Leaps by Bayer, Hitachi Ventures, and Hat Technology Fund 4 from its ~$80M Series D closed July 2024. It has raised $296M-$367.6M total and has no IPO as of July 2026.
- Is Huma a safe company to join in 2026?
- Mixed signals. Huma has made at least five acquisitions since 2022 and partnered with Eckuity Capital in May 2025 to fund M&A, showing growth activity, but has had no new priced funding round in over two years and operates in a sector with high-profile collapses like Babylon and Sensyne Health.
- Who is Huma's biggest competitor?
- In remote patient monitoring, peers include Biofourmis, Current Health, BioIntelliSense, Glooko, and Validic, while incumbent Medtronic's CareLink competes in device-tethered remote monitoring. Its Hi Scribe AI tool competes directly with ambient-scribe features from Epic and Oracle Health as of 2025.
- What is Huma's valuation in 2026?
- Huma was valued near $1 billion after its ~$80M Series D closed in July 2024, per Bloomberg reporting from July 16, 2024. Forge Global's secondary market data lists a Series D-1 post-money valuation of $731.49M as of April 2024, with no confirmed new priced round since.
Timeline
- 2026-06-23Samsung partnership announced for biomarker development and clinical endpoints
- 2025-06-05Hi Scribe AI documentation tool reported live across 870 practices
- 2025-05-16Eckuity Capital M&A partnership announced; acquired Aluna (Knox Medical Diagnostics)
- 2025-04-17Health Canada Class II SaMD medical device license granted
- 2025-01-01Wheel Health platform-as-a-service partnership announced
- 2024-10-02Acquired eConsult for approximately GBP 41.5M, launched Huma Workspace
- 2024-08-26Saudi FDA Class C medical device certification secured
- 2024-07-16Series D closed at approximately $80M, valuation near $1 billion, Huma Cloud Platform launched with GenAI
- 2023-06-12US FDA 510(k) Class II clearance for disease-agnostic SaMD platform
- 2023-03-23EU MDR Class IIb regulatory approval for multi-condition SaMD
Revision history
29 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- wikipedia.org (Huma (company)) (2026-07-29)
- Huma - Overview, News & Similar companies (2026-07-06)
- Huma Raises $80 Million Reaching Near-$1 Billion Valuation (2024-07-16)
- Huma completes Series D... launches Huma Cloud Platform GenAI (2024-07-16)
- Huma Announces Partnership with Eckuity Capital to Accelerate M&A and Acquires Aluna (2025-05-16)
- Huma Therapeutics Receives Health Canada Class II Medical Device License (2025-04-17)
- Huma receives multi-condition US FDA 510(k) Class II regulatory clearance (2023-06-12)
- Huma acquires eConsult and launches Huma Workspace for Health Systems (2024-10-02)
- Huma Deploys Hi Scribe to Automate Clinical Documentation and Billing Using AI (2025-06-05)
- Working at Huma (2026-02-28)
- Huma 2026 Company Profile: Valuation, Funding & Investors
- Newsroom (2026-06-22)